Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2012

View Archived Issues

Strategies to overcome drug resistance in mutation-dependent cancers

Varenicline as a potential treatment for methamphetamine dependence

New antibodies presented for P. falciparum infection

Merck & Co. patents novel SYK inhibitors for respiratory disorders

Development of a novel, simple to use, non-radiological neuropathy-detection technology

Joint grant awarded for prostate cancer drug research

Scientists at Rhizen Pharmaceuticals present new PI3K inhibitors

Photocure discloses initial results from phase IIb trial of Cevira

Synta Pharmaceuticals discloses new inhibitors of CRAC and cytokine production

Type I interferon receptor 1 MAb evaluated in patients with scleroderma

Omeros patents new anti-MASP-2 monoclonal antibodies

Constellation Pharmaceuticals presents novel BRD4 inhibitors

First-in-patient trial data updated for PF-03084014

Japanese group divulges new agents for Helicobacter pylori infections

Preliminary phase I data presented on MLN-0128 for advanced solid malignancies

Cerecor signs option with Johns Hopkins for DAAO inhibitor platform

IMI launches new drug development projects

Peregrine Pharmaceuticals advances Cotara into pivotal phase III trial

RXi Pharmaceuticals begins second phase I study of anti-scarring drug

Thomson Reuters announces newest intelligence solution for drug development

Vical licenses adjuvant to Cyvax for malaria vaccines

FDA approves La Jolla Pharmaceutical's IND for CKD drug

Japan Tobacco applies for approval of single-tablet anti-HIV regimen in Japan

CLAVELA study completes enrollment

Gentium to begin phase I development of defibrotide in Japan

Regulatory approvals received for new study of Vacc-4x

Protalix and Pfizer sign new agreement for clinical development of Elelyso

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....